Education
About Us
Working with TipRanks
Follow Us
Bergenbio Asa (BRRGF)
:BRRGF
Earnings Data
Report Date
May 21, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.1Same Quarter Last Year
Moderate Buy
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: 0.00%
|Next Earnings Date:May 21, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment, with positive developments in the BGB16 study and financial management, but faced setbacks with program discontinuations and the CEO's upcoming departure.Company Guidance
During the Q3 2024 earnings call for BerGenBio, several key metrics and guidance were provided. The company reported a 20% decrease in year-to-date operating expenses, totaling NOK 117.9 million compared to NOK 148.3 million in 2023. The cash position at the end of the third quarter was approximately NOK 175 million, down from NOK 200 million at the end of the second quarter, yet still within the guidance of a NOK 40 million quarterly burn rate. BerGenBio anticipates the first interim analysis of the Phase IIa study for bemcentinib in STK11 mutated non-small cell lung cancer patients to occur in early 2025. Despite some site activation delays, the company remains optimistic about enrolling the targeted 40 patients. The current cash reserves are expected to fund operations through the third quarter of 2025, with final Phase III enrollment anticipated by then. The guidance reiterated the financial and strategic focus on the bemcentinib program, emphasizing the significant unmet medical need and market potential for STK11 mutated patients.Encouraging Safety Profile for BGB16 Study
Completed enrollment in the Phase Ib study of bemcentinib in frontline therapy for STK11 mutated non-small cell lung cancer, with an encouraging safety profile and plasma levels in the therapeutic window.
Reduction in Operating Expenses
Year-to-date operating expenses decreased by 20% to NOK 117.9 million from NOK 148.3 million in 2023.
Significant Market Opportunity for Bemcentinib
The potential market for bemcentinib plus standard of care therapy is estimated at USD 4 billion annually, targeting 30,000 eligible patients with STK11 mutations in the Western world.
Fast Track Designation by FDA
Bemcentinib has received fast track designation from the FDA for use in non-small cell lung cancer with STK11 mutations.
Financial Guidance Maintained
Cash position at the end of Q3 was NOK 175 million, projected to finance operations into Q3 2025, maintaining guidance of NOK 40 million burn rate per quarter.
BRRGF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BRRGF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 21, 2025 | $0.02 | $0.02 | 0.00% |
Feb 26, 2025 | $0.02 | $0.02 | 0.00% |
Nov 13, 2024 | $0.02 | $0.02 | 0.00% |
Aug 21, 2024 | $0.02 | $0.02 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bergenbio Asa (BRRGF) report earnings?
Bergenbio Asa (BRRGF) is schdueled to report earning on May 21, 2025, TBA Not Confirmed.
What is Bergenbio Asa (BRRGF) earnings time?
Bergenbio Asa (BRRGF) earnings time is at May 21, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BRRGF EPS forecast?
Currently, no data Available